biostudies-literatureOverman MJAmerican Cancer SocietyNCI NIH HHSNational Institutes of Health139-144https://www.ebi.ac.uk/biostudies/studies/S-EPMC5834085biostudies-literatureUnknown29(1)<h4>Background</h4>Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC.<h4>Patients and methods</h4>The primary objective was Response Evaluation Criteria in Solid Tumors version 1.1 response rate. Eligibility included Eastern Cooperative Oncology Group performance status 0/1, refractory disease, and SBA or CIMP-high metastatic CRC. Nab-paclitaxel was inAnnals of oncology : official journal of the European Society for Medical OncologyPhase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.PMC5834085P30 CA016672127343-RSG-15-068-01-TBGAdam LKopetz SAzad NVilar EOverman MJWang JWolff RPisanic TRFogelman DDasari ARaghav KMorris JShroff RKarunasena EKee BEng CfalsePhase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.<h4>Background</h4>Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC.<h4>Patients and methods</h4>The primary objective was Response Evaluation Criteria in Solid Tumors version 1.1 response rate. Eligibility included Eastern Cooperative Oncology Group performance status 0/1, refractory disease, and SBA or CIMP-high metastatic CRC. Nab-paclitaxel was in2018-01-01T00:00:00Z2018 Jan2025-04-19T15:17:39.04Z2019-03-26T22:26:58ZS-EPMC58340852906927910.1093/annonc/mdx688